e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Asthma: risk factors and effect of anti-IgE
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres
M. Britton, T. Howes, D. Saralaya, D. Hepburn, M. Nordstrom, K. Welham, K. Regan, I. Kasujee (Chertsey, Colchester, Bradford, Frimley/Camberley, United Kingdom)
Source:
Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Session:
Asthma: risk factors and effect of anti-IgE
Session type:
Poster Discussion
Number:
227
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Britton, T. Howes, D. Saralaya, D. Hepburn, M. Nordstrom, K. Welham, K. Regan, I. Kasujee (Chertsey, Colchester, Bradford, Frimley/Camberley, United Kingdom). Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres. Eur Respir J 2012; 40: Suppl. 56, 227
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Pavic Michelle - 02.09.2012 11:52
Hi, I have found the data from your psoter to be quite interesting and was wodnering if you could email me a copy at: michelle.pavic@novartis.com. Thanks.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands
Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care
Year: 2007
Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta
Source: International Congress 2016 – Asthma management
Year: 2016
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis
Source: Virtual Congress 2020 – Management of allergy, asthma and COPD
Year: 2020
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study.
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept